Key Insights

Highlights

Success Rate

83% trial completion

Published Results

379 trials with published results (23%)

Research Maturity

1058 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.0%

217 terminated out of 1664 trials

Success Rate

83.0%

-3.6% vs benchmark

Late-Stage Pipeline

9%

154 trials in Phase 3/4

Results Transparency

36%

379 of 1058 completed with results

Key Signals

379 with results83% success217 terminated

Data Visualizations

Phase Distribution

1,401Total
Not Applicable (185)
Early P 1 (13)
P 1 (487)
P 2 (562)
P 3 (141)
P 4 (13)

Trial Status

Completed1,058
Terminated217
Unknown151
Recruiting99
Withdrawn69
Active Not Recruiting42

Trial Success Rate

83.0%

Benchmark: 86.5%

Based on 1058 completed trials

Clinical Trials (1664)

Showing 20 of 20 trials
NCT07524530Phase 2Not Yet Recruiting

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

NCT07737418Not ApplicableNot Yet RecruitingPrimary

Dyadic Physical Activity Intervention for Children Undergoing Cancer Treatment

NCT07740174Not ApplicableNot Yet RecruitingPrimary

Efficacy of Seated Exercise on Functional Capacity and Quality of Life in Patients With Leukemia During Chemotherapy Cycles

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT06021600Phase 1TerminatedPrimary

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

NCT00400946Phase 3Completed

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

NCT05645718Phase 2RecruitingPrimary

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT04898790Not ApplicableRecruitingPrimary

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

NCT06152809Phase 1Recruiting

CIML NK Cells With Venetoclax for AML

NCT07374315Not ApplicableNot Yet RecruitingPrimary

Weight Gain in Pediatric Leukemia Survivors

NCT03226704Enrolling By InvitationPrimary

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

NCT03934372Phase 1Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT06053268Not ApplicableActive Not RecruitingPrimary

Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors

NCT04504526Early Phase 1Recruiting

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

NCT02251548Phase 2Active Not Recruiting

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

NCT07714044Not Yet Recruiting

Rutgers University Study of the Genetics of Blood Cancers

NCT00342888CompletedPrimary

Case-Control Study of Pesticides and Childhood Leukemia

NCT05237986Recruiting

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT06795139Not ApplicableCompletedPrimary

Pilot of a Trial Enrollment Diversity Dashboard

NCT01515527Phase 2RecruitingPrimary

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Scroll to load more

Research Network

Activity Timeline